1. Home
  2. PCRX vs AUTL Comparison

PCRX vs AUTL Comparison

Compare PCRX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • AUTL
  • Stock Information
  • Founded
  • PCRX 2006
  • AUTL 2014
  • Country
  • PCRX United States
  • AUTL United Kingdom
  • Employees
  • PCRX N/A
  • AUTL N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • AUTL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PCRX Health Care
  • AUTL Health Care
  • Exchange
  • PCRX Nasdaq
  • AUTL Nasdaq
  • Market Cap
  • PCRX 1.2B
  • AUTL 590.8M
  • IPO Year
  • PCRX 2011
  • AUTL 2018
  • Fundamental
  • Price
  • PCRX $26.59
  • AUTL $2.17
  • Analyst Decision
  • PCRX Buy
  • AUTL Strong Buy
  • Analyst Count
  • PCRX 10
  • AUTL 3
  • Target Price
  • PCRX $29.30
  • AUTL $10.20
  • AVG Volume (30 Days)
  • PCRX 892.8K
  • AUTL 1.1M
  • Earning Date
  • PCRX 02-27-2025
  • AUTL 03-13-2025
  • Dividend Yield
  • PCRX N/A
  • AUTL N/A
  • EPS Growth
  • PCRX N/A
  • AUTL N/A
  • EPS
  • PCRX N/A
  • AUTL N/A
  • Revenue
  • PCRX $694,957,000.00
  • AUTL $10,091,000.00
  • Revenue This Year
  • PCRX $5.14
  • AUTL $851.83
  • Revenue Next Year
  • PCRX $2.44
  • AUTL $224.65
  • P/E Ratio
  • PCRX N/A
  • AUTL N/A
  • Revenue Growth
  • PCRX 4.40
  • AUTL 82.71
  • 52 Week Low
  • PCRX $11.16
  • AUTL $2.07
  • 52 Week High
  • PCRX $31.67
  • AUTL $7.37
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 77.75
  • AUTL 41.81
  • Support Level
  • PCRX $25.06
  • AUTL $2.11
  • Resistance Level
  • PCRX $27.10
  • AUTL $2.26
  • Average True Range (ATR)
  • PCRX 1.45
  • AUTL 0.12
  • MACD
  • PCRX 0.28
  • AUTL 0.01
  • Stochastic Oscillator
  • PCRX 86.23
  • AUTL 27.78

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Share on Social Networks: